Novartis division begins Phase III clinical trials
The Filgrastim study is intended to assess the efficacy and safety of Sandoz’s biosimilar filgrastim versus Amgen’s Neupogen in breast cancer patients eligible for myelosuppressive chemotherapy treatment. The
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.